For some people, cancer immunotherapies are life-changing. These treatments can turn the body's own immune system against a ...
H.C. Wainwright initiated coverage on Virax Biolabs Group Limited (NASDAQ:VRAX), a U.K.-based company focused on detecting immune responses and diagnosing viral diseases. Virax Biolabs is developing T ...
The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients ...
Lung cancer is the leading cause of cancer-related deaths globally, with most patients diagnosed at an advanced stage 1. Systemic therapies are often undermined by individual resistance mechanisms ...
Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success.
This article provides a regulatory perspective on secondary malignancy of T-cell origin as a rare adverse reaction to the currently marketed CD19- or BCMA-directed chimeric antigen receptor (CAR) ...
Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...
An international research team with strong participation from DTU has developed a new biotechnological platform that makes it possible to test and understand advanced cancer treatments much faster and ...
T-cells are the immune system's frontline defenders with a crucial role in controlling HIV. In a milestone clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results